Date register of trial

Trials for date register in the RPCEC

Date of Registration Public title Sponsor State
2010-12-28 InCarbacel-II CIGB Registered
2008-10-16 FASECU I CIGB Registered
2008-09-18 Tisuacryl® in Dental Hyperesthesia BIOMAT Registered
2010-12-27 Hebervis administration in patients suffering from buccal mucositis caused by chemotherapy [unsealed CIGB Registered
2010-12-24 CIGB-128 administration to patients with surgically-treated keloids. CIGB Registered
2010-12-24 Application of CIGB-128 in keloid patients undergoing surgical exeresis. CIGB Registered
2009-02-26 CITOPROT-III CIGB Registered
2008-07-29 A phase II study of the Cuban adult formulation tetanus and diphtheria vaccine. FINLAY Registered
2008-07-29 A phase II study of the Cuban vaccine against tetanus and diphtheria VA-DIFTET. FINLAY Registered
2010-12-17 Advanced breast cancer treatment with hR3 monoclonal antibody combined with doxorubicin and cyclophosphamide, phase I. CIM Registered
2008-07-29 Clinical trial to evaluate the safety, reactogenicity and immunogenicity of the vax-TyVi vaccine in volunteers between 18 and 20 years of age. FINLAY Registered
2008-07-29 A phase I/II study to evaluate the Salmonella Typhi Vi polysaccharide vaccine – vax-TyVi – in children and teenagers. FINLAY Registered
2010-12-27 Clinical trial, phase II: Evaluation of TheraCIM hR3 MaB combined with chemo- and radio-therapy to treat patients with epithelial tumors in neck of the uterus, stage III. CIM Registered
2008-09-19 Phase I-II study of live oral cholera vaccine 638 in healthy adult volunteers in Cuba. FINLAY Registered
2010-12-24 InCCNM -I CIGB Registered
2008-09-12 Phase Ib-IIb trial of the live oral cholera vaccine 638 in adult volunteers in Mozambique. FINLAY Registered
2009-12-24 InCroMiel I CIGB Registered
2008-07-29 Post marketing clinical trial to evaluate the reactogenicity profile of the Cuban vaccine against diphtheria, tetanus, and pertussis infections in infants. FINLAY Registered
2010-12-24 Clinical trial, phase II, to evaluate rhEGF efficacy and safety at a dose of 25 or 75 micrograms intralesionally in patients with diabetic foot ulcer (Wagner grade 1 or 2). CIGB Registered
2010-12-24 Pharmacokinetics of intralesional EGF in patients with diabetic foot ulcers. CIGB Registered